DOCSLIB.ORG

NOVO NORDISK SCHERING-PLOUGH BOEHRINGER-INGELHEIMMAY 2008 75 NOVO NORDISK He Pharm Exec 50 for 2008 Ac- We Assembled This Year’S 50

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NOVO NORDISK SCHERING-PLOUGH BOEHRINGER-INGELHEIMMAY 2008 75 NOVO NORDISK He Pharm Exec 50 for 2008 Ac- We Assembled This Year’S 50 # PHARMACEUTICAL EXECUTIVE NOVO NORDISK SCHERING-PLOUGH BOEHRINGER-INGELHEIMMAY 2008 www.pharmexec.com 75 NOVO NORDISK he Pharm Exec 50 for 2008 ac- we assembled this year’s 50. In the past, THE PHARM EXEC 50 counted for prescription drug sales private companies that did not disclose PFIZER1. Pfizer Tof more than $510 billion. Inter- sales figures were omitted. Starting 2. GlaxoSmithKline estingly, except for Pfizer, GSK, Sanofi- this year, we’re offering estimates. This 3. Sanofi-Aventis Aventis (numbers one through three, mostly affects privately owned European 4. Novartis respectively), and Watson (number 50), companies such as Menarini, Servier, 5. AstraZeneca every company on the list showed posi- and Ratiopharm, though it also means a 6. Johnson & Johnson TAKEDA 7. Merck tive growth last year, including some first time ranking for Procter & Gamble, solid double-digit performances. whose multi-billion dollar pharmaceuti- 8. Roche Much of that growth was driven by cal operation is such a small part of the 10. Eli Lilly 11. Bristol-Myers Squibb mergers, of which there were many. Ny- company that P&G declines to break out 12. Bayer comed, for example, almost tripled in size the figures by sales of human prescrip- 13. Abbott after its purchase of Altana, itself a top tion drugs and vaccines, as reported in 14. Amgen 50 company. And because rankings in the annual reports and SEC filings. 15. Boehringer-Ingelheim Pharm Exec 50 are calculated in US dol- We do not count royalty revenue, con- 16. Schering-Plough lars, a number of European companies tract manufacturing, or animal health, 17. Takeda look better than they might have if re- and OTC is excluded as far as the docu- 18. Genentech ported in their native currencies. (Roche’s ments allow. Some accompanying charts 19. Teva SCHERING-PLOUGHprescription drug revenue, for instance, are based on figures from IMS health. 20. Novo Nordisk grew by 11 percent in Swiss francs, but These are calculated differently, and 21. Astellas more than 20 percent in US dollars.) may disagree with numbers cited in the 22. Daiichi Sankyo We made one key change in the way 50 itself. 23. Merck KGaA 24. Eisai 25. Otsuka PHARM EXEC TOP 50 26. Servier 27. UCB 28. Baxter 29. Nycomed 30. Solvay 31. Gilead Sciences GENENTECH32. Genzyme THEWINNERS’ 33. Forest 34. Menarini 35. Allergan $ $ $ 36. Mitsubishi Tanabe 37. Chugai 38. P&G BAYER39. Ratiopharm CIRCLE 40. CSL Pharma may be taking a hit, but a 41. Barr Pharmaceuticals surprising number of the Pharm Exec 50 42. Alcon 43. Mundipharma turned in double-digit growth last year. 44. Shire 45. Biogen Idec Sure, some of that is a matter of mergers 46. Stada and the falling dollar, and the giants at 47. King Pharmaceuticals ROCHE 48. Lundbeck 49. Actavis the top of the list actually lost sales. But 50. Watson the industry’s elite still features players who know how to hit the bullseye. BY PHARM EXEC STAFF LILLY 76 PHARMACEUTICALPE EXECUTIVE50 MAY 2008 www.pharmexec.com Rank Company & Headquarters 2007 Global Pharma R&D Spend 2007 Top-Selling Drugs [‘06 Rank] [Web site] Sales [change from 2006] [2007 sales] Pfizer $45.1 B [-1.5%] $8.1 B Lipitor [$12.7 B] [1] pfizer.com] Norvasc [$3.0 B] 1 New York, NY [ Celebrex [$2.3 B] GlaxoSmithKline $39.2 B [-2.7%] $6.4 B Seretide/Advair [$6.9 B] [2] gsk.com] Lamictal [$2.2 B] 2 London, England [ Valtrex [$1.9 B] Sanofi-Aventis $37.4 B [-1.4%] $6.5 B Lovenox [$3.8 B] [3] sanofi-aventis.com] Plavix [$3.5 B] 3 Paris, France [ Lantus [$3.0 B] Novartis $29.5 B [9.3%] $6.4 B Diovan [$5.0 B] [4] novartis.com] Gleevec [$3.1 B] 4 Basel, Switzerland [ Zometa [$1.3 B] AstraZeneca $25.7 B [11.5%] $5.1 B Nexium [$5.2 B] [5] astrazeneca.com] Seroquel [$4.0 B] 5 London, England [ Crestor [$2.8 B] Johnson & Johnson $23.3 B [7.0%] $5.3 B Remicade [$4.7 B] [6] jnj.com] Procrit [$2.9 B] 6 New Brunswick, NJ [ Topamax [$2.5 B] Merck $22.6 B [6.9%] $4.9 B Singulair [$4.2 B] [7] merck.com] Cozaar/Hyzaar [$3.4 B] 7 Whitehouse Station, NJ [ Fosamax [$3.0 B] Roche $16.9 B [20.3%] $6.7 B MabThera/Rituxan [$4.9 B] [8] roche.com] Herceptin [$4.3 B] 8 Basel, Switzerland [ Avastin [$3.6 B] Wyeth $15.7 B [18.8%] $3.1 B Effexor [$3.8 B] [10] wyeth.com] Prevnar [$2.4 B] 9 Madison, NJ [ Enbrel [$2.0 B] Eli Lilly $14.8 B [19.0%] $3.5 B Zyprexa [$4.8 B] [9] lilly.com] Cymbalta [$2.1 B] 10 Indianapolis, IN [ Gemzar [$1.6 B] [Key Insights on the Top 10] Pfizer: Shares hit a 10-year low GlaxoSmithKline: Cuts cost of AstraZeneca: In February, lung Merck: Vytorin gets slammed in April 2008 with profit falling AIDS medication to impoverished cancer drug Recentin failed to in the press after a study reveals 18 percent // Voluntarily pulls countries // NIH trial reveals meet its endpoint in clinical trials that it is no better than generics popular Lipitor ads after it was that Avandia does not lead to // FDA concludes that Prilosec for reducing arterial plaque // revealed that spokesperson heart risks // Purchases Reliant and Nexium do not lead to heart In January, a federal grand jury Dr. Jarvik was not a licensed Pharma for $1.65 billion // problems // Study reveals that investigates Merck for off-label cardiologist // Chantix comes Avandia receives black box for Crestor does not reduce the risk promotion of Vioxx under fire as people blog about heart attacks // Andrew Witty is of death in older people that adverse reactions; Pfizer beefs up named CEO in October 2007 suffer from heart failure Lilly: The company is slammed warnings // Viagra turns 10 // with lawsuits claiming it withheld announces in January that it will Sanofi-Aventis: Plavix patent Johnson & Johnson: Sued Zyprexa’s side effects cut 10,000 jobs // Exhubera is upheld in New York court, generic by Arkansas over marketing of voluntarily pulled off the market sales by Apotex halted Risperdal // Launches DTC ad Wyeth: Pristiq approved for campaign for Cordis drug-eluting depression // Releases generic Roche: Avastin is approved for Novartis: In December Novartis stents // Establishes three new version of heartburn drug Protonix breast cancer // Roche’s Tamiflu announced that it would axe divisions to handle surgical // Announces that it will cut receives stronger psychiatric 2,500 full time jobs // Ludwig technologies, chronic conditions, 50,000 employees over warning // Judge temproarily Hantson is named CEO of and potential growth areas // three years halts sales of Mircera until lawsuit Novartis North America // Pays Settles Ortho-Evra suit for with Amgen over Aranesp patents $11 billion for Nestle’s eye care $1.25 million ends // In January, Roche picked division Alcon up Ventana for $3.4 billion // Recalls AIDS drug Viracept 78 PHARMACEUTICALPE EXECUTIVE50 MAY 2008 www.pharmexec.com Rank Company & Headquarters 2007 Global Pharma R&D Spend 2007 Top-Selling Drugs [‘06 Rank] [Web site] Sales [change from 2006] [2007 sales] Bristol-Myers Squibb $13.9 B [12.7%] $3.3 B Plavix [$4.8 B] [11] bms.com] Abilify [$1.7 B] 11 New York, NY [ Avapro/Avalide [$1.2 B] Bayer $9.87 B [51.9%] $3.8 B Yasmin [$1.5 B] 12[15] Leverkusen, Germany [bayer.com] Abbott $12.4 B [18.0%] $2.5 B Humira [$3.0 B] 13[13] Abbott Park, IL [abbott.com] Amgen $13.9 B [3.3%] $3.2 B Aranesp [$3.6 B] 14[12] Thousand Oaks, CA [amgen.com] Boehringer-Ingelheim $10.9 B [15.4%] $2.4 B Spiriva [$2.6 B] 15[14] Ingelheim, Germany 0 2 4 6 8 10 [boehringer-ingelheim.com] TOP 10 US PRODUCTS OF 2007 GLOBAL PHARMACEUTICAL SALES BY REGION, 2007 Product [Maker] 2007 Sales in billions Growth in Sales Percent of Global Sales Market 2007 Sales (US$B) % Growth from 2006 1. Lipitor [Pfizer] $8.1 -6.9% North America $304.5 4.2% 2. Nexium [AstraZeneca] $5.5 5.8% Europe $206.2 6.7% 3. Advair Diskus [GlaxoSmithKline] $4.3 7.5% Japan $62.2 13.1% 4. Plavix [Sanofi-Aventis/BMS] $3.9 30% 31.1% Asia*, Africa, and Australia $58.5 4.2% 5. Seroquel[AstraZeneca] $3.5 16.7% Latin America $32 12% 45.9% 6. Singulair[Merck] $3.4 13.3% *Excluding Japan SOURCE: IMS MIDAS, MAT December 2007 Plavix was 7. Enbrel[Amgen/Wyeth] $3.4 9.7% 9.4% 8. Prevacid[Tap Pharmaceuticals] $3.4 % -5.6% 307 TOP 10 R&D SPEND 9. Aranesp [Amgen] $3.2 UP 2007 -20% 8.8% Company Total R&D Spend US billions 10. Epogen [Amgen] $3.1 -3.1% SOURCE: IMS Heatlh 4.8% 1. Pfizer $8.1 2. Roche $6.7 The global pharmaceutical 3. Sanofi-Aventis $6.6 TOP 10 GLOBAL PRODUCTS OF 2007 [31] t); IMS (left) Product [Maker] 2007 Sales in billions Growth in Sales market grew by 4. Novartis $6.4 1. Lipitor [Pfizer] $13.5 -2.8% PERCENT 5. GSK $6.4 2. Plavis [Sanofi-Aventis/BMS] $7.3 20.5% 6.4 percent OF EMERGING 6. J&J $5.3 3. Nexium [AstraZeneca] $7.2 5.3% to approximately MARKETS’ SHARE 7. AstraZeneca $5.1 4. Seretide/Advair [GlaxoSmithKline] $7.1 9.6% 2007 8. Merck $4.9 5. Enbrel [Amgen/Wyeth] $5.3 l growthowth 15.3% Dec OF GROWTH IN 9.
Load more

Recommended publications
  • Appendix a 2016 Financial Report Financial Review Pfizer Inc
    Appendix A 2016 Financial Report Financial Review Pfizer Inc. and Subsidiary Companies GLOSSARY OF DEFINED TERMS Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2016 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 2016 Financial Report, most of which are explained or defined below: 2016 Financial Report This Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 2016 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2016 AAV Adeno-Associated Virus ABO Accumulated postretirement benefit obligation ACA (Also referred to as U.S. U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Healthcare Legislation) Act. ACIP Advisory Committee on Immunization Practices ALK anaplastic lymphoma kinase Allergan Allergan plc Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us AM-Pharma AM-Pharma B.V. Anacor Anacor Pharmaceuticals, Inc. Astellas Astellas Pharma U.S. Inc. ASU Accounting Standards Update ATM-AVI aztreonam-avibactam Bamboo Bamboo Therapeutics, Inc. Baxter Baxter International Inc. BMS Bristol-Myers Squibb Company CDC U.S. Centers for Disease Control and Prevention Cellectis Cellectis SA Celltrion Celltrion Inc. and Celltrion Healthcare,
    [Show full text]
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical
    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
    [Show full text]
  • 1 United States District Court for the Southern District
    Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 1 of 167 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF IOWA, CENTRAL DIVISION THE STATE OF IOWA, Plaintiff, v. ABBOTT LABORATORIES, INC., AGOURON PHARMACEUTICALS, INC., JURY TRIAL REQUESTED ALPHARMA, INC., ALZA CORPORATION, AMGEN, INC., ASTRAZENECA L.P., ASTRAZENECA PHARMACEUTICALS, LP., AVENTIS BEHRING L.L.C., COMPLAINT BARR LABORATORIES, INC., BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE CORPORATION, BAYER CORPORATION, BAYER PHARMACEUTICALS CORPORATION, BEN VENUE LABORATORIES, INC., BOEHRINGER INGELHEIM CORPORATION, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY, CENTOCOR, INC., CHIRON CORPORATION, DERMIK LABORATORIES, INC., DEY, INC., DEY, L.P., ELI LILLY AND COMPANY, EMD, INC., ENDO PHARMACEUTICALS, INC., ETHEX CORPORATION, ETHICON, INC., FOREST LABORATORIES, INC., FOREST PHARMACEUTICALS, INC. GENEVA PHARMACEUTICALS, GLAXOSMITHKLINE, PLC, GLAXOWELLCOME, INC., GREENSTONE, LTD., HOECHEST MARION ROIUSSEL, INC., HOFFMAN-LAROCHE, INC., 1 Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 2 of 167 IMMUNEX CORPORATION, IVAX CORPORATION, IVAX PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA PRODUCTS, LP, JOHNSON & JOHNSON, KING PHARMACEUTICALS, INC., KING RESEARCH AND DEVELOPMENT, MCNEIL-PPC, INC., MEDIMMUNE, INC., MERCK & CO., INC., MONARCH PHARMACEUTICALS, INC., MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., NOVARTIS PHARMACEUTICALS CORPORATION, NOVOPHARM USA, INC., ONCOLOGY THERAPEUTICS NETWORK CORP., ORTHO-MCNEIL PHARMACEUTICAL, INC.,
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I
    Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I. Imaging Systems Corp A.L.I. Technologies (International) LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Pharmaceutical Products Group Abbott Point of Care Division Abbott Vascular Division Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Advanced Neuromodulation Systems, Inc. Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allen Medical Systems, Inc. Allergan Sales, LLC Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alpharma Pharmaceuticals, Inc. Alpharma Pharmaceuticals, LLC AMAG Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 AMATECH Corporation American Medical Distributors, Inc. 100 New Highway N Amityville NY 11701 American Medical System,
    [Show full text]
  • Advanced Sterilization Products Alpharma Pharmaceuticals
    Manufacturers/Wholesalers Street City ST Zip Abbott Diabetes Care Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Abbott Nutrition Abbott Pharmaceutical Products Group Abbott Point of Care Abbott Spine Abbott Vascular Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Anna CA 92705 Advanced Neuromodulation Systems, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Agencourt Bioscience Corporation Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allergan American, LLC. Allergan Holdings, Inc, Allergan Puerto Rico Holdings, Inc. Allergan Sales Allergan Sales Puerto Rico, Inc. Allergan Specialty Therapeutics, Inc. Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Allscripts, LLC. 2401 Commerce Drive Libertyville IL 60048 Alpharma Pharmaceuticals, LLC 1 New England Ave Piscataway NJ 08854 American Medical System, Inc 10700 Bren Road West Minnetonka MN 55343 Ameridose, LLC. 50 Fountain Street Framingham MA 01702 Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA AMO Sales and Service, Inc. Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 AMS- AMS Innovation Center 3070 Orchard Drive San Jose CA 95134 AMS Sales Corporation 10700 Bren Road West Minnetonka MN 55343 Amylin Pharmaceutical, Inc. 9360 Towne Center Drive San Diego CA 92121 Anda Pharmaceuticals, Inc.
    [Show full text]
  • Table of Contents
    Table of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in drug delivery dealmaking 2.1. Introduction 2.2. Drug delivery partnering over the years 2.3. Bigpharma drug delivery dealmaking activity 2.4. Big biotech drug delivery dealmaking activity 2.5. Most active drug delivery dealmakers 2.6 Drug delivery partnering by deal type 2.7. Drug delivery partnering by disease type 2.8. Partnering by drug delivery technology type 2.9. Average deal terms for drug delivery partnering 2.9.1 Drug delivery headline values 2.9.2 Drug delivery upfront payments 2.9.3 Drug delivery milestone payments 2.9.4 Drug delivery royalty rates 2.10. The anatomy of drug delivery partnering 2.11. Drug delivery or specialty pharma? 2.11.1. Is specialty pharma the only way for drug delivery? 2.11.2. Best practice for optimizing drug delivery program development 2.11.3. The anatomy of a drug delivery deal 2.11.3.a. Case study 1: Alpharma – Durect 2.11.3.b. Case study 2: Bayer – MDRNA 2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences Chapter 3 – Leading drug delivery deals 3.1. Introduction 3.2. Top drug delivery deals by value Chapter 4 – Bigpharma drug delivery deals 4.1. Introduction 4.2. How to use bigpharma drug delivery partnering deals 4.3. Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Endo Pharmaceuticals Forest Laboratories Galderma Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Merck & Co Merck KGaA Mylan Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Shionogi Shire Takeda Teva UCB Valeant Warner Chilcott Chapter 5 – Bigbiotech drug delivery deals 5.1.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Sponsors Experience
    sponsors experience Abbott Eli Lilly Merck & Co. Sano-Aventis Aegerion Emergent Biosolutions Merz Pharmaceuticals Sano-Pasteur Allergen Exact Sciences Metabasis Therapeutics Sano-Synthelabo Alpharma Forbes Medi-Tech Nabi Pharmaceuticals Schering-Plough Altana Forest NanoBio Schwarz Pharmaceuticals Amgen Furiex Neuraxon Searle Amylin G&W Labs Neurogen Shionogi Arena Pharmaceuticals Galderma Novartis Solvay Astellas Genentech Novavax Stiefel Laboratories AstraZeneca Genomic Collaboration Noven Pharmaceuticals Surface Logix Aventis Gilead Novo Nordisk Takeda Barr GlaxoSmithKline Omthera Pharmaceuticals TAP Baxter Healthcare GlaxoSmithKline Biologicals Ortho McNeil Taro Pharmaceuticals Bayer Healthcare Glaxo Wellcome Pain Therapeutics Teva Pharmaceuticals Berlex Glenmark Pharmaceuticals Palatin Therapeutics Tioga Bertek Hoechst-Marion Roussel PaxVax TorreyPintes Therapeutics Bionovo Homan LaRoche Pharmacia Triangle Biovail IDEA AG Pharmos Corporation Trimel Biopharma Boehringer Ingelheim Impax Laboratories Pzer Tylenol Bristol-Myers Squibb Insmed Pozen UCB Centocor Jazz Pharmaceuticals Procter & Gamble Vanguard Cipher Johnson & Johnson ProEthic Vaxinnate Collagenex King Pharmaceuticals Promius Pharmaceuticals Viro Pharma Covidien KOS Pharmaceuticals QLT Warner Chilcott Daiichi Sankyo KOWA Pharmaceuticals Quinnova Pharmaceuticals Watson Pharmaceuticals DepoMed Lexicon Pharmaceuticals Rhone-Poulenc Rorer Wyeth Dow Marine Polymer Technologies Roche Wyeth Ayerst Dupont Merck Meade Johnson Roche Diagnostics Xenoport Duramed Medimmune R.W.T. XOMA LTD Dynport Vaccine Company Medivir Sankyo Yamanouchi If you would like more details about a potential clinical study opportunity with Coastal Carolina Research Center please contact: Nathan Morton Director of Business Development Phone #: 843-856-3784 Fax #: 843-856-3788 Email: [email protected] Study Experience Sponsors Experience CRO Experience.
    [Show full text]
  • [Docket No. FDA-2013-N-0845] Bracco Diagnostics E
    This document is scheduled to be published in the Federal Register on 07/19/2013 and available online at http://federalregister.gov/a/2013-17324, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2013-N-0845] Bracco Diagnostics et al.; Withdrawal of Approval of 52 New Drug Applications and 77 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 52 new drug applications (NDAs) and 77 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: Effective [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6366, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No. Drug Applicant NDA 011620 Cardiografin (diatrizoate meglumine Bracco Diagnostics, 107 College Rd.
    [Show full text]
  • 05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 04:25:50 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2016 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • 08/06/2016 Provider Subsystem Healthcare and Family Services Run Time: 00:10:55 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/06/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 00:10:55 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2016 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]